Published in Mol Cell Biol on January 01, 2003
Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta (2009) 1.89
Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A (2004) 1.53
Distinct roles of RalA and RalB in the progression of cytokinesis are supported by distinct RalGEFs. EMBO J (2008) 1.48
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res (2008) 1.43
Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci U S A (2005) 1.38
The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. Genes Cancer (2011) 1.32
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett (2007) 1.31
Regulation of TOR by small GTPases. EMBO Rep (2012) 1.24
RalA interacts with ZONAB in a cell density-dependent manner and regulates its transcriptional activity. EMBO J (2004) 1.22
Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem (2011) 1.20
Ral GTPases regulate neurite branching through GAP-43 and the exocyst complex. J Cell Biol (2005) 1.17
Phospholipase D signaling: orchestration by PIP2 and small GTPases. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.09
RalA activation at nascent lamellipodia of epidermal growth factor-stimulated Cos7 cells and migrating Madin-Darby canine kidney cells. Mol Biol Cell (2004) 1.00
Heterogeneity of phosphatidic acid levels and distribution at the plasma membrane in living cells as visualized by a Föster resonance energy transfer (FRET) biosensor. J Biol Chem (2010) 0.93
Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis. J Biol Chem (2014) 0.88
Podosomes and Invadopodia: Related structures with Common Protein Components that May Promote Breast Cancer Cellular Invasion. Breast Cancer (Auckl) (2008) 0.77
ADP-Ribosylation Factor 1 Regulates Proliferation, Migration, and Fusion in Early Stage of Osteoclast Differentiation. Int J Mol Sci (2015) 0.75
Ral-Arf6 crosstalk regulates Ral dependent exocyst trafficking and anchorage independent growth signalling. Cell Signal (2016) 0.75
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell (1999) 6.42
ADP-ribosylation factor, a small GTP-dependent regulatory protein, stimulates phospholipase D activity. Cell (1993) 5.75
Phosphatidylinositol 4-phosphate 5-kinase alpha is a downstream effector of the small G protein ARF6 in membrane ruffle formation. Cell (1999) 4.98
Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol (1999) 4.94
Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem (1996) 4.50
GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat Cell Biol (2001) 4.42
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
A regulatory role for ARF6 in receptor-mediated endocytosis. Science (1995) 3.82
A human exchange factor for ARF contains Sec7- and pleckstrin-homology domains. Nature (1996) 3.54
Activation of ARF6 by ARNO stimulates epithelial cell migration through downstream activation of both Rac1 and phospholipase D. J Cell Biol (2001) 3.49
The role of ARF and Rab GTPases in membrane transport. Curr Opin Cell Biol (1999) 3.42
Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. Mol Cell (1999) 3.35
Phospholipase D: a downstream effector of ARF in granulocytes. Science (1994) 3.33
H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol Cell Biol (2000) 3.24
Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol (1997) 3.22
Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family. J Biol Chem (1995) 3.10
Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem (1998) 2.75
Molecules in the ARF orbit. J Biol Chem (1998) 2.66
EFA6, a sec7 domain-containing exchange factor for ARF6, coordinates membrane recycling and actin cytoskeleton organization. EMBO J (1999) 2.63
ARF6 targets recycling vesicles to the plasma membrane: insights from an ultrastructural investigation. J Cell Biol (1998) 2.49
Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases. Mol Cell Biol (1995) 2.45
Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J (1996) 2.44
Involvement of Ral GTPase in v-Src-induced phospholipase D activation. Nature (1995) 2.16
Type I phosphatidylinositol 4-phosphate 5-kinase isoforms are specifically stimulated by phosphatidic acid. J Biol Chem (1994) 2.14
Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. J Biol Chem (1999) 2.02
Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem (1999) 1.99
Role for phospholipase D in receptor-mediated endocytosis. Mol Cell Biol (2001) 1.96
ADP-ribosylation factor 6 regulates actin cytoskeleton remodeling in coordination with Rac1 and RhoA. Mol Cell Biol (2000) 1.91
Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem (1998) 1.82
Activation of rat brain phospholipase D by ADP-ribosylation factors 1,5, and 6: separation of ADP-ribosylation factor-dependent and oleate-dependent enzymes. Proc Natl Acad Sci U S A (1994) 1.74
Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem (2001) 1.72
Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett (2000) 1.70
Phospholipase D1: a key factor for the exocytotic machinery in neuroendocrine cells. EMBO J (2001) 1.67
Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Res Commun (2000) 1.64
Activation of the small GTPase Ral in platelets. Mol Cell Biol (1998) 1.58
Neutrophil phospholipase D is activated by a membrane-associated Rho family small molecular weight GTP-binding protein. J Biol Chem (1993) 1.48
Ras-dependent activation of the small GTPase Ral. Curr Biol (1998) 1.42
Regulated exocytosis in chromaffin cells. Translocation of ARF6 stimulates a plasma membrane-associated phospholipase D. J Biol Chem (1998) 1.41
ARF-GEP(100), a guanine nucleotide-exchange protein for ADP-ribosylation factor 6. Proc Natl Acad Sci U S A (2001) 1.41
ARF and PITP restore GTP gamma S-stimulated protein secretion from cytosol-depleted HL60 cells by promoting PIP2 synthesis. Curr Biol (1996) 1.39
Phospholipase D and RalA cooperate with the epidermal growth factor receptor to transform 3Y1 rat fibroblasts. Mol Cell Biol (2000) 1.39
Binding site of brefeldin A at the interface between the small G protein ADP-ribosylation factor 1 (ARF1) and the nucleotide-exchange factor Sec7 domain. Proc Natl Acad Sci U S A (2000) 1.34
Suppression of Ras-induced apoptosis by the Rac GTPase. Mol Cell Biol (1999) 1.26
v-Src increases diacylglycerol levels via a type D phospholipase-mediated hydrolysis of phosphatidylcholine. Mol Cell Biol (1991) 1.26
Functional association between Arf and RalA in active phospholipase D complex. Proc Natl Acad Sci U S A (1998) 1.24
Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem Biophys Res Commun (2001) 1.23
Caveolae, transmembrane signalling and cellular transformation. Mol Membr Biol (1995) 1.20
A role for phospholipase D1 in neurotransmitter release. Proc Natl Acad Sci U S A (2001) 1.20
Localization and possible functions of phospholipase D isozymes. Biochim Biophys Acta (1999) 1.20
Traps to catch unwary oncogenes. Trends Genet (1998) 1.19
Localization of phospholipase D in detergent-insoluble, caveolin-rich membrane domains. Modulation by caveolin-1 expression and caveolin-182-101. J Biol Chem (1999) 1.16
RalA interacts directly with the Arf-responsive, PIP2-dependent phospholipase D1. Biochem Biophys Res Commun (1997) 1.16
Colocalization of phospholipase D1 and GTP-binding-defective mutant of ADP-ribosylation factor 6 to endosomes and lysosomes. FEBS Lett (1999) 1.14
Antagonistic effects of protein kinase C alpha and delta on both transformation and phospholipase D activity mediated by the epidermal growth factor receptor. Mol Cell Biol (1999) 1.10
Phospholipase D stimulation by receptor tyrosine kinases mediated by protein kinase C and a Ras/Ral signaling cascade. J Biol Chem (1999) 1.10
Identification of a plasma membrane-associated guanine nucleotide exchange factor for ARF6 in chromaffin cells. Possible role in the regulated exocytotic pathway. J Biol Chem (2000) 1.09
Ras mediates the activation of phospholipase D by v-Src. J Biol Chem (1995) 1.09
RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene (1999) 1.09
Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells. Oncogene (1994) 1.07
Antigen-stimulated activation of phospholipase D1b by Rac1, ARF6, and PKCalpha in RBL-2H3 cells. Mol Biol Cell (2002) 1.06
v-Src activates a unique phospholipase D activity that can be distinguished from the phospholipase D activity activated by phorbol esters. Biochem J (1993) 1.03
Ral and Rho-dependent activation of phospholipase D in v-Raf-transformed cells. Biochem Biophys Res Commun (1999) 1.01
Phospholipase D. Ann N Y Acad Sci (2000) 0.97
Activation of phospholipase D1 by direct interaction with ADP-ribosylation factor 1 and RalA. FEBS Lett (1998) 0.97
Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling. Oncogene (2002) 0.94
ADP-ribosylation factor proteins mediate agonist-induced activation of phospholipase D. J Biol Chem (1998) 0.93
Phospholipase D1 in caveolae: regulation by protein kinase Calpha and caveolin-1. Biochemistry (1999) 0.93
ARF proteins mediate insulin-dependent activation of phospholipase D. Curr Biol (1997) 0.92
Mitogenic phospholipase D activity is restricted to caveolin-enriched membrane microdomains. Biochem Biophys Res Commun (2000) 0.91
Crosstalk between ARF6 and protein kinase Calpha in Fc(gamma)RI-mediated activation of phospholipase D1. Curr Biol (2001) 0.89
Specific inhibition of phorbol ester-stimulated phospholipase D by Clostridium sordellii lethal toxin and Clostridium difficile toxin B-1470 in HEK-293 cells. Restoration by Ral GTPases. J Biol Chem (1998) 0.89
Phosphatidylcholine-specific phospholipase D activity is elevated in v-Fps-transformed cells. Biochem Biophys Res Commun (1994) 0.88
The activation of phospholipase D by endothelin-1, angiotensin II, and platelet-derived growth factor in vascular smooth muscle A10 cells is mediated by small G proteins of the ADP-ribosylation factor family. Endocrinology (2000) 0.86
Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-iota. Biochem J (2001) 0.83
Ras protein is involved in the physiological regulation of phospholipase D by platelet derived growth factor. Oncogene (2000) 0.82
Elevated phospholipase D activity induces apoptosis in normal rat fibroblasts. Biochem Biophys Res Commun (2002) 0.81
Defective phospholipase D activation in Ki-ras-transformed NIH3T3 cells: evidence for downstream effector of PLC-gamma 1 in PDGF-mediated signal transduction. Biochem Biophys Res Commun (1995) 0.80
Effects of brefeldin A on phosphatidylcholine phospholipase D and inositolphospholipid metabolism in HL-60 cells. Eur J Biochem (1997) 0.80
Which Ras rides the raft? Nat Cell Biol (2001) 0.79
Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci (2010) 3.35
Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol (2008) 2.85
ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol (2009) 2.82
ARF6-GTP recruits Nm23-H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly. Nat Cell Biol (2002) 2.63
Neuropilins: structure, function and role in disease. Biochem J (2008) 2.45
The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol (2008) 2.39
Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem (2008) 2.38
Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol (2005) 2.19
Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene (2003) 2.13
The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival. FASEB J (2004) 1.85
Phospholipase D couples survival and migration signals in stress response of human cancer cells. J Biol Chem (2006) 1.78
The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras via phospholipase D2. Nat Cell Biol (2007) 1.72
ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci U S A (2004) 1.71
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res (2008) 1.60
Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene (2005) 1.58
Endocytosis resumes during late mitosis and is required for cytokinesis. J Biol Chem (2005) 1.53
Localization and activation of the ARF6 GTPase during cleavage furrow ingression and cytokinesis. J Biol Chem (2002) 1.47
Modulation of Rac1 and ARF6 activation during epithelial cell scattering. J Biol Chem (2003) 1.44
High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle (2011) 1.44
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res (2008) 1.43
Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc Natl Acad Sci U S A (2006) 1.41
ADP-ribosylation factor 6 regulates glioma cell invasion through the IQ-domain GTPase-activating protein 1-Rac1-mediated pathway. Cancer Res (2009) 1.40
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo. Cancer Res (2009) 1.37
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett (2007) 1.31
ARF6-mediated endocytic recycling impacts cell movement, cell division and lipid homeostasis. Semin Cell Dev Biol (2010) 1.30
Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells. Mol Cell Biol (2011) 1.30
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol (2009) 1.28
Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci U S A (2002) 1.24
Finishing the job: cytoskeletal and membrane events bring cytokinesis to an end. Exp Cell Res (2004) 1.23
Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem (2011) 1.20
Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun (2003) 1.20
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol (2011) 1.19
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res (2009) 1.18
Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. Am J Pathol (2003) 1.17
Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells. Biochemistry (2004) 1.16
Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS One (2013) 1.15
Association of a clinical knowledge support system with improved patient safety, reduced complications and shorter length of stay among Medicare beneficiaries in acute care hospitals in the United States. Int J Med Inform (2008) 1.15
Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochem J (2011) 1.14
Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A (2006) 1.14
Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol (2005) 1.12
ARF6-dependent activation of ERK and Rac1 modulates epithelial tubule development. EMBO J (2007) 1.11
The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal (2013) 1.10
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol (2014) 1.08
Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat (2011) 1.08
A requirement for ARF6 during the completion of cytokinesis. Exp Cell Res (2005) 1.07
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res (2005) 1.07
mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem (2005) 1.03
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res (2011) 1.03
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res (2003) 1.02
p130Cas: a key signalling node in health and disease. Cell Signal (2012) 1.01
Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. Cell Cycle (2015) 1.01
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res (2003) 1.00
Suppression of TGF-beta signaling by phospholipase D. Cell Cycle (2007) 0.98
Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett (2006) 0.98
Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol (2004) 0.97
Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys (2005) 0.97
Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas (2010) 0.97
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res (2010) 0.96
Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res (2013) 0.95
Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett (2010) 0.95
Suppression of cell migration by protein kinase Cdelta. Oncogene (2005) 0.94
Downregulating PKC delta provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression. Oncogene (2002) 0.94
Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling. Oncogene (2002) 0.94
Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells. Biochem Biophys Res Commun (2002) 0.94
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol (2009) 0.94
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biol Blood Marrow Transplant (2005) 0.94
Proteasome-mediated degradation of Rac1-GTP during epithelial cell scattering. Mol Biol Cell (2006) 0.93
Phase I study of nelfinavir in liposarcoma. Cancer Chemother Pharmacol (2012) 0.93
Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nat Cell Biol (2002) 0.93
Establishing epithelial glandular polarity: interlinked roles for ARF6, Rac1, and the matrix microenvironment. Mol Biol Cell (2012) 0.91
Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. J Biol Chem (2003) 0.91
A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair. PLoS One (2012) 0.90
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New Drugs (2010) 0.90
The role of neuropilins in cell signalling. Biochem Soc Trans (2009) 0.90
Investigating the role of ADP-ribosylation factor 6 in tumor cell invasion and extracellular signal-regulated kinase activation. Methods Enzymol (2005) 0.90
Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet (2012) 0.90
Simultaneous angular multiplexing optical projection tomography at shifted focal planes. Opt Lett (2013) 0.89
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma (2014) 0.89
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res (2010) 0.89
Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest. Cancer Lett (2013) 0.89
Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy. J Support Oncol (2012) 0.88
Unregulated ARF6 activation in epithelial cysts generates hyperactive signaling endosomes and disrupts morphogenesis. Mol Biol Cell (2010) 0.88
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res (2009) 0.87
The association between hospital outcomes and diagnostic imaging: early findings. J Am Coll Radiol (2009) 0.86
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs (2005) 0.86
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest (2008) 0.86
ARF6-mediated endosome recycling reverses lipid accumulation defects in Niemann-Pick Type C disease. PLoS One (2009) 0.86
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol (2011) 0.86
Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol Cancer Ther (2014) 0.85
A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant (2011) 0.84